Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Hillmen · SciRah

Researcher profile · Semantic Scholar

P. Hillmen

Share profile

P. Hillmen — researcher profile on SciRah

h-index: 94
Works: 649
Citations: 46K

Most-cited papers

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
J. Byrd, P. Hillmen, P. Ghia, A. Kater +20 more
2021Journal of Clinical Oncology493 citations Open access
Semantic Scholar
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Jennifer R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak +24 more
2022New England Journal of Medicine373 citations Open access
Semantic Scholar
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
P. Hillmen, J. Szer, I. Weitz, A. Röth +15 more
2021New England Journal of Medicine306 citations Open access
Semantic Scholar
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
P. Barr, C. Owen, T. Robak, A. Tedeschi +15 more
2022Blood Advances253 citations Open access
Semantic Scholar
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
C. Tam, Jennifer R. Brown, B. Kahl, P. Ghia +27 more
2022The Lancet Oncology205 citations Open access
Semantic Scholar
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
A. Kater, J. Wu, T. Kipps, B. Eichhorst +24 more
2020Journal of Clinical Oncology195 citations Open access
Semantic Scholar
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
T. Munir, David A. Cairns, A. Bloor, D. Allsup +28 more
2023New England Journal of Medicine121 citations Open access
Semantic Scholar
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
H. Parry, G. McIlroy, R. Bruton, Myah Ali +13 more
2021Blood Cancer Journal114 citations Open access
Semantic Scholar
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
C. Tam, T. Robak, P. Ghia, B. Kahl +22 more
2020Haematologica98 citations Open access
Semantic Scholar
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
P. Hillmen, A. Pitchford, A. Bloor, A. Broom +28 more
2023The Lancet Oncology96 citations Open access
Semantic Scholar
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia.
J. Byrd, J. Woyach, R. Furman, P. Martin +13 more
2021Blood93 citations Open access
Semantic Scholar
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
W. Wierda, A. Rawstron, F. Cymbalista, X. Badoux +17 more
2021Leukemia78 citations Open access
Semantic Scholar
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
P. Hillmen, B. Eichhorst, Jennifer R. Brown, N. Lamanna +24 more
2022Journal of Clinical Oncology71 citations Open access
Semantic Scholar
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018
S. Richards, D. Painter, A. J. Dickinson, M. Griffin +13 more
2021European Journal of Haematology61 citations Open access
Semantic Scholar
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
Jennifer R. Brown, J. Byrd, P. Ghia, J. Sharman +11 more
2021Haematologica60 citations Open access
Semantic Scholar
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
R. de Latour, J. Szer, I. Weitz, A. Röth +14 more
2022The Lancet Haematology59 citations Open access
Semantic Scholar
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
P. Robbe, K. Ridout, D. Vavoulis, H. Dreau +37 more
2022Nature Genetics58 citations Open access
Semantic Scholar
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study
T. Eyre, A. Schuh, W. Wierda, Jennifer R. Brown +11 more
2021The Lancet Haematology54 citations
Semantic Scholar
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
R. Furman, J. Byrd, R. Owen, S. O'Brien +19 more
2021Leukemia48 citations Open access
Semantic Scholar
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
R. Bomben, F. Rossi, F. Vit, T. Bittolo +33 more
2021Clinical Cancer Research40 citations Open access
Semantic Scholar
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
T. Munir, S. Girvan, David A. Cairns, A. Bloor +30 more
2025New England Journal of Medicine36 citations Open access
Semantic Scholar
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
J. Byrd, P. Hillmen, P. Ghia, A. Kater +16 more
202136 citations
Semantic Scholar
Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial
A. Tedeschi, E. Ferrant, I. Flinn, C. Tam +10 more
2021Blood30 citations Open access
Semantic Scholar
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
E. Tausch, Philipp Beck, R. Schlenk, Billy Jebaraj +17 more
2020Haematologica30 citations Open access
Semantic Scholar
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
P. Hillmen, A. Pitchford, A. Bloor, A. Broom +23 more
2021Blood28 citations Open access
Semantic Scholar
Management of cardiovascular complications of bruton tyrosine kinase inhibitors
C. P. S. Tang, G. Lip, T. McCormack, A. Lyon +7 more
2021British Journal of Haematology27 citations Open access
Semantic Scholar
Guideline for the treatment of chronic lymphocytic leukaemia
R. Walewska, N. Parry-Jones, T. Eyre, G. Follows +7 more
2022British Journal of Haematology26 citations
Semantic Scholar
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL).
B. Kahl, K. Giannopoulos, W. Jurczak, M. Šimkovič +25 more
2022Clinical Lymphoma, Myeloma & Leukemia25 citations
Semantic Scholar
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
D. Rossi, M. Shadman, A. Condoluci, Jennifer R. Brown +7 more
2020HemaSphere22 citations Open access
Semantic Scholar
Pegcetacoplan versus Eculizumab in PNH. Reply.
P. Hillmen, A. Risitano, R. Peffault de Latour
2021New England Journal of Medicine20 citations
Semantic Scholar
The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients
D. Payne, S. Dalal, Richard M. Leach, R. Parker +12 more
2021bioRxiv19 citations Open access
Semantic Scholar
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper
T. Eyre, J. Riches, P. Patten, R. Walewska +4 more
2021British Journal of Haematology18 citations Open access
Semantic Scholar
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
P. Barr, C. Owen, T. Robak, A. Tedeschi +16 more
202118 citations
Semantic Scholar
SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP
Tamara Davenne, J. Klintman, Sushma Sharma, R. Rigby +9 more
2020Cell Reports18 citations Open access
Semantic Scholar
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
T. Munir, A. Pitchford, A. Bloor, A. Broom +23 more
2021Blood17 citations Open access
Semantic Scholar
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia
D. Howard, A. Hockaday, Julia M. Brown, W. Gregory +5 more
2021Trials15 citations Open access
Semantic Scholar
MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
T. Munir, L. Cherrill, N. Webster, S. Dalal +17 more
2022Blood13 citations Open access
Semantic Scholar
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
Wei-Yu Lin, S. Fordham, N. Sunter, C. Elstob +32 more
2021Nature Communications13 citations Open access
Semantic Scholar
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry
B. Höchsmann, F. Sicre de Fontbrune, J. W. Lee, A. Kulagin +4 more
2022European Journal of Haematology12 citations Open access
Semantic Scholar
CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Jennifer R. Brown, P. Hillmen, B. Eichhorst, N. Lamanna +16 more
2022Clinical Lymphoma, Myeloma & Leukemia12 citations
Semantic Scholar
Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
P. Hillmen, Jing Xie, A. Yong, C. Waweru +3 more
2021eJHaem12 citations Open access
Semantic Scholar
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab
F. Macrae, Barnaby Peacock-Young, P. Bowman, S. Baker +11 more
2020American journal of hematology/oncology12 citations Open access
Semantic Scholar
Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
T. Munir, A. Pitchford, A. Bloor, A. Pettitt +22 more
2022Blood11 citations Open access
Semantic Scholar
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study
P. Hillmen, D. Cairns, A. Bloor, D. Allsup +26 more
2023Blood10 citations Open access
Semantic Scholar
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
P. Ghia, S. Coutre, B. Cheson, J. Barrientos +6 more
2020Haematologica9 citations Open access
Semantic Scholar
Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years
C. de Castro, B. Mulherin, Christopher J. Patriquin, V. Selvaratnam +7 more
2023Blood8 citations Open access
Semantic Scholar
S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
P. Hillmen, A. Pitchford, A. Bloor, A. Pettitt +24 more
2022HemaSphere7 citations Open access
Semantic Scholar
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
A. Pepper, A. Zucchetto, K. Norris, E. Tissino +14 more
2021Leukemia7 citations Open access
Semantic Scholar
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.
M. Holmes, G. Scott, Samuel Heaton, Tyler Barr +9 more
2023Molecular Therapy: Oncolytics6 citations Open access
Semantic Scholar
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria
A. Pike, C. McKinley, Briony Forrest, Rebecca Scott +19 more
2022The Lancet Haematology6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Ghia×14
Invite
P. Ghia — researcher profile on SciRah
A. Schuh×13
Invite
A. Schuh — researcher profile on SciRah
T. Robak×11
Invite
T. Robak — researcher profile on SciRah
Jennifer R. Brown×11
Invite
Jennifer R. Brown — researcher profile on SciRah

×11

Invite

A. Hockaday — researcher profile on SciRah

Invite

T. Munir — researcher profile on SciRah

Invite

D. Allsup — researcher profile on SciRah

Invite

W. Jurczak — researcher profile on SciRah

Invite

D. Howard — researcher profile on SciRah

Invite

P. Patten — researcher profile on SciRah

Invite

S. Paneesha — researcher profile on SciRah

N. Pemberton×8

Invite

N. Pemberton — researcher profile on SciRah